Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows

News

BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4826 (Published 11 December 2020) Cite this as: BMJ 2020;371:m4826

Read our latest coverage of the coronavirus outbreak

Changing Dynamics of COVID-19 in the U.S. with the Emergence of the Delta Variant: Projections of the COVID-19 Simulator
- Abstract
- Fulltext
- PDF
Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan
- Abstract
- Fulltext
- PDF
The impact of COVID-19 vaccination campaigns accounting for antibody-dependent enhancement
- Abstract
- Fulltext
- PDF
Covid-19: Where are we on vaccines and variants?
- Abstract
- Fulltext
- PDF
Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis
- Abstract
- Fulltext
- PDF
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination
- Abstract
- Fulltext
- PDF
Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected
- Abstract
- Fulltext
- PDF
Covid-19: Assess the effects of extending Pfizer vaccine dosing interval, expert urges
- Abstract
- Fulltext
- PDF
Viral Variants and Vaccinations: If We Can Change the COVID-19 Vaccine... Should We?
- Abstract
- Fulltext
- PDF
Covid-19: Logistical problems frustrate GPs ready to deliver vaccine in England
- Abstract
- Fulltext
- PDF